180 related articles for article (PubMed ID: 28618914)
1. Role of the polypill for secondary prevention in ischaemic heart disease.
Castellano JM; Fuster V; Jennings C; Prescott E; Bueno H
Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):44-51. PubMed ID: 28618914
[TBL] [Abstract][Full Text] [Related]
2. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
Bramlage P; Sims H; Minguet J; Ferrero C
Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
[TBL] [Abstract][Full Text] [Related]
3. A polypill strategy to improve adherence: results from the FOCUS project.
Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
[TBL] [Abstract][Full Text] [Related]
4. Polypill and global cardiovascular health strategies.
Sanz G; Fuster V
Semin Thorac Cardiovasc Surg; 2011; 23(1):24-9. PubMed ID: 21807295
[TBL] [Abstract][Full Text] [Related]
5. Improving adherence to medication for secondary cardiovascular disease prevention.
Keenan J
Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):29-35. PubMed ID: 28618909
[TBL] [Abstract][Full Text] [Related]
6. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
López-Jaramillo P; González-Gómez S; Zarate-Bernal D; Serrano A; Atuesta L; Clausen C; Castro-Valencia C; Camacho-Lopez P; Otero J
Ther Adv Cardiovasc Dis; 2018 Jun; 12(6):169-174. PubMed ID: 29546816
[TBL] [Abstract][Full Text] [Related]
7. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V
J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532
[TBL] [Abstract][Full Text] [Related]
8. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
Tamargo J; Castellano JM; Fuster V
Int J Cardiol; 2015 Dec; 201 Suppl 1():S15-22. PubMed ID: 26747390
[TBL] [Abstract][Full Text] [Related]
9. The cardiovascular polypill: clinical data and ongoing studies.
Castellano JM; Bueno H; Fuster V
Int J Cardiol; 2015 Dec; 201 Suppl 1():S8-14. PubMed ID: 26747391
[TBL] [Abstract][Full Text] [Related]
10. [The polypill in cardiovascular prevention: successful through simplification? : New study results on the benefit of the polypill strategy in primary and secondary prevention].
Despang P; Schikora M; Doehner W
Inn Med (Heidelb); 2023 Jun; 64(6):598-604. PubMed ID: 37227456
[TBL] [Abstract][Full Text] [Related]
11. Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease.
González-Juanatey JR; Mostaza JM; Lobos JM; Abarca B; Llisterri JL; Baron-Esquivias G; Galve E; Lidón RM; Garcia-Moll FX; Sánchez PL; Suárez C; Millán J; Pallares V; Alemán JJ; Egocheaga I
Med Clin (Barc); 2017 Feb; 148(3):139.e1-139.e15. PubMed ID: 27993410
[TBL] [Abstract][Full Text] [Related]
12. The cardiovascular polypill in high-risk patients.
Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
[TBL] [Abstract][Full Text] [Related]
13. Polypill: quo vadis?
Muscente F; De Caterina R
J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):783-92. PubMed ID: 27341194
[TBL] [Abstract][Full Text] [Related]
14. Polypills for the prevention of Cardiovascular diseases.
Kolte D; Aronow WS; Banach M
Expert Opin Investig Drugs; 2016 Nov; 25(11):1255-1264. PubMed ID: 27645895
[TBL] [Abstract][Full Text] [Related]
15. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease.
Wood F; Salam A; Singh K; Day S; Jan S; Prabhakaran D; Rodgers A; Patel A; Thom S; Ward H
BMJ Open; 2015 Sep; 5(9):e008018. PubMed ID: 26423850
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
[TBL] [Abstract][Full Text] [Related]
17. The concept of the polypill in the prevention of cardiovascular disease.
Wiley B; Fuster V
Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
[TBL] [Abstract][Full Text] [Related]
18. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population.
Sanz G; Fuster V
Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):101-10. PubMed ID: 19104519
[TBL] [Abstract][Full Text] [Related]
19. [Fixed-dose compounds and the secondary prevention of ischemic heart disease].
Fuster V; Sanz G
Rev Esp Cardiol; 2011 Jul; 64 Suppl 2():3-9. PubMed ID: 21807282
[TBL] [Abstract][Full Text] [Related]
20. Patient preferences for a polypill for the prevention of cardiovascular diseases.
Laba TL; Howard K; Rose J; Peiris D; Redfern J; Usherwood T; Cass A; Patel A; Jan S
Ann Pharmacother; 2015 May; 49(5):528-39. PubMed ID: 25680761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]